Latest news with #RajeshSGokhale


News18
31-07-2025
- Health
- News18
ITBP-DBT forge partnership to address challenges faced by border guarding troops
Agency: PTI New Delhi, Jul 31 (PTI) The ITBP, responsible for guarding the Line of Actual Control (LAC) with China, has signed an agreement with the Department of Biotechnology (DBT) to find scientific solutions for the health and environmental challenges faced by troops at high-altitude locations. As part of the Memorandum of Understanding (MoU), the experts from the two sides will work to tackle issues like high-altitude sickness, low oxygen (hypoxia) and extreme cold conditions, an official statement said. They will also find ways to bring diagnostic tools and telemedicine to remote border posts and do research work to improve diet, stress relief methods and genetic studies for better adaptation to harsh climates, an Indo-Tibetan Border Police (ITBP) spokesperson said. The agreement was signed by the officials from the two sides in the presence of DBT Secretary Rajesh S Gokhale and ITBP Director General Rahul Rasgotra, he said. The DBT functions under the Ministry of Science and Technology. The MoU also aims to hold regular interactions between DBT scientists and ITBP medical teams to stay updated with the latest innovations, the spokesperson said. He said development of special nutrition packs, emergency medical kits and cold-weather health gear for the troops is also a subject of work as part of this partnership. The ITBP's nearly 90,000 personnel are primarily tasked with guarding the 3,488-km-long LAC, apart from rendering a variety of duties in the internal security domain of the country under the Union home ministry. PTI NES DIV DIV (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: July 31, 2025, 20:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.


News18
24-06-2025
- Science
- News18
Axiom Mission-4's Delay Prompts Scientists To Revise Experiments, Prepare Fresh Samples
Last Updated: The mission had finalised a total of 60 experiments representing 31 countries, including the US, India, Poland, Hungary, Saudi Arabia and Nigeria, for 14 days As Axiom Mission-4 continues to face delays, scientists are revising research plans with some experiments now requiring a fresh set of samples. Initially scheduled for liftoff on June 8, liftoff to the International Space Station is indefinitely on hold. 'While the microbial samples can endure extended delays without compromising viability, the stem cell cultures remain stable for only a few days. Beyond that window, they lose experimental value, so fresh samples will need to be prepared and sent once a new launch date is confirmed," said Dr Rajesh S Gokhale, secretary, department of biotechnology (DBT). Of the seven experiments shortlisted by Indian Space Research Organization (ISRO), at least three were designed by institutes under DBT. Two of the experiments used microbe samples – one to study how microgravity affects edible microalgae, and the other to investigate how photosynthetic cyanobacteria grow when fed with urea versus nitrate – to explore their role in future life-support systems for astronauts. The third experiment is aimed at studying how microgravity affects muscle repair and regeneration, and how metabolic supplements can help. This was based on pre-cultured human muscle stem cells, likely sourced from healthy human donors. Since cultured stem cells have a limited viability window, typically three to eight days, these samples will need to be discarded and used afresh. MISSION AWAITS LIFTOFF DATE To be led by former NASA astronaut Peggy Whitson, the mission has Group Captain Shubhanshu Shukla as pilot, with two mission specialists from the European Space Agency (ESA) – Sławosz Uznański-Wiśniewski from Poland and Tibor Kapu of Hungary. US-based Axiom Space had finalised a total of 60 experiments representing 31 countries, including the US, India, Poland, Hungary, Saudi Arabia and Nigeria, for the 14-day mission, which was initially expected to take off on SpaceX Falcon 9 from Kennedy Space Centre in Florida. It was hailed as one of the most extensive sets of experiments ever planned for a mission aboard the ISS. Some of India's top research institutes, including Indian Institute of Science (IISc) in Bengaluru, International Centre for Genetic Engineering and Biotechnology (ICGEB), Institute for Stem Cell Science and Regenerative Medicine (InStem), and the Indian Institute of Space Science and Technology (IIST) had contributed to the seven experiments shortlisted by ISRO. These included studies on edible microalgae – the tiny, nutrient-rich organisms that could be a future food source for long-term space missions – as well as experiments to improve future life-support systems for astronauts by investigating growth of photosynthetic cyanobacteria, and studying how tardigrades (a type of microbe) survives and reproduces in microgravity. Researchers were also keen to study the cognitive impact of computer screens on astronauts, which will help design more user-friendly spacecraft computers in future. Additionally, there were experiments designed to study how salad seeds sprout in space, and how microgravity affects growth and development of food crop seeds like fenugreek. 'India-centric food experiments including the sprouting of fenugreek (methi) known for its medicinal properties and sprouts will help us explore their behaviour in microgravity. We'll bring the seeds back to Earth for cultivation and assess how microgravity affects their growth across generations. These studies will form the foundation for future space farming," Tushar Phadnis, Group Head for Microgravity Platforms and Research, ISRO, had said earlier. First Published:


Mint
23-06-2025
- Business
- Mint
Indias biotech sector grew nearly fivefold in past decade: DBT Secretary
New Delhi, Jun 23 (PTI) India's biotechnology sector has expanded rapidly in the past decade, with its bioeconomy growing from USD 35.5 billion in 2014 to USD 165.7 billion in 2024, according to Rajesh S Gokhale, Secretary, Department of Biotechnology (DBT). He said the sector is now aiming for a USD 300 billion target by 2030, as scientific advances begin to translate into industrial and public health gains. "Biotechnology is no longer a fringe discipline, it's now a strategic driver for India's economic and health priorities," Gokhale said at a press conference highlighting 11 years of DBT's achievements. Among the standout initiatives is GenomeIndia, a nationwide effort to sequence the genomes of 10,000 individuals from 99 population groups, he said. The data, released earlier this year, is expected to inform personalised medicine and help researchers develop diagnostics tailored to Indian populations. Gokhale also highlighted India's first in-human gene therapy trial using a lentiviral vector for Severe Hemophilia A. India's vaccine response, Gokhale said, demonstrated the capacity of the DBT-backed innovation ecosystem. Under "Mission COVID Suraksha", five COVID-19 vaccines developed with DBT support received emergency approvals, including GEMCOVAC-19, the world's first thermostable mRNA vaccine. Other products include the intranasal COVID-19 vaccine and CERVAVAC, India's first indigenous quadrivalent HPV vaccine, now part of the National Immunization Programme, according to document shared at the briefing. Indian scientists contributed to decoding the complex genome of bread wheat, a global staple crop, and published a reference genome with 94 per cent coverage. Other research showed how Mycobacterium tuberculosis can infect liver cells and undermine TB treatment efficacy, while a study on taurine levels suggested amino acid may influence aging. Gokhale said India's biotech startup landscape has changed dramatically, with over 10,000 startups now in the sector, up from a few hundred a decade ago. Over 800 biotech products have emerged in this period. Through BIRAC, DBT has helped set up 95 bio-incubators across 21 states. Infrastructure investments include India's first dedicated biomanufacturing institute in Mohali and vaccine testing labs notified as Central Drug Laboratories. Speed breeding facilities have also been established to accelerate the development of climate-resilient crops. The BioE3 policy, approved by the Cabinet in 2024, is aimed at fostering high-performance biomanufacturing aligned with Net Zero targets.